Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8123507 | 0.78 | S1PR4 (0.43) | KDM4EL3MBTL1S1PR4MAPTTGFBR1 | |
| SCHEMBL7234381 | 0.78 | S1PR4 (0.43) | KDM4EL3MBTL1S1PR4MAPTTGFBR1 | |
| SCHEMBL12093603 | 0.78 | KDM4E (0.52) | KDM4EL3MBTL1S1PR4MAPTNQO2 | |
| SCHEMBL10304986 | 0.78 | RAB9A (0.45) | KDM4EL3MBTL1MAPTNQO2KMT2A | |
| SCHEMBL8062500 | 0.78 | MAPT (0.42) | KDM4EL3MBTL1MAPTNQO2ACHE | |
| SCHEMBL4977234 | 0.78 | KDM4E (0.52) | KDM4EL3MBTL1MAPTTGFBR1NQO2 | |
| SCHEMBL4573187 | 0.76 | KDM4E (0.50) | KDM4EL3MBTL1MAPTNQO2MEN1 | |
| SCHEMBL19088185 | 0.76 | KDM4E (0.50) | KDM4EL3MBTL1MAPTNQO2MEN1 | |
| SCHEMBL2462970 | 0.76 | S1PR4 (0.47) | KDM4EL3MBTL1S1PR4MAPTNQO2 | |
| SCHEMBL6608419 | 0.76 | NQO2 (0.43) | KDM4EL3MBTL1MAPTNQO2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| WO-2023130054-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2023-07-06 | — | — | WO | disclosed |
| WO-2021061898-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2021-04-01 | — | — | WO | disclosed |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200131142-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2020-04-30 | — | — | US | disclosed |
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| EP-2997029-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2079731-B1 | NOVEL SUBSTITUTED PIPERIDYL-PROPANE-THIOLS | BOEHRINGER INGELHEIM INT (DE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
| CN-1882589-B | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP | 2010-06-09 | — | — | CN | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090022047-A1 | OPTICAL RECORDING MEDIUM AND METHOD OF RECORDING VISIBLE INFORMATION | FUJIFILM CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090022047-A1 | OPTICAL RECORDING MEDIUM AND METHOD OF RECORDING VISIBLE INFORMATION | FUJIFILM CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| CN-101180297-A | Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-1882589-A | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2006-12-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | KDM4E 1025/4885L3MBTL1 3339/4885S1PR4 243/4885 |
| US-20200131142-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885S1PR4 337/4885 |
| US-20200131129-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | KDM4E 4790/4885L3MBTL1 4422/4885S1PR4 337/4885 |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KDM4E 950/4885L3MBTL1 2574/4885S1PR4 4341/4885 |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | ZC3HAV1, ZC3HAV1L, RPL35 | KDM4E 473/4885L3MBTL1 4873/4885S1PR4 2593/4885 |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | KDM4E 382/4885L3MBTL1 1136/4885S1PR4 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.